CN105833237A - Pharmaceutical composition for treating coronary heart disease and preparation method and application thereof - Google Patents

Pharmaceutical composition for treating coronary heart disease and preparation method and application thereof Download PDF

Info

Publication number
CN105833237A
CN105833237A CN201610383024.9A CN201610383024A CN105833237A CN 105833237 A CN105833237 A CN 105833237A CN 201610383024 A CN201610383024 A CN 201610383024A CN 105833237 A CN105833237 A CN 105833237A
Authority
CN
China
Prior art keywords
parts
radix
heart disease
coronary heart
chinese medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610383024.9A
Other languages
Chinese (zh)
Inventor
姚宗芹
李光彩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yishui Central Hospital Of Linyi
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610383024.9A priority Critical patent/CN105833237A/en
Publication of CN105833237A publication Critical patent/CN105833237A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/074—Ganoderma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/344—Codonopsis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/51—Gentianaceae (Gentian family)
    • A61K36/515—Gentiana
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/79—Schisandraceae (Schisandra family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/894—Dioscoreaceae (Yam family)
    • A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses a pharmaceutical composition for treating coronary heart disease and a preparation method and application thereof and belongs to the technical field of traditional Chinese medicine. The effective components of the pharmaceutical composition comprise, by weight, 20-30 parts of radix astragali, 2-3 parts of typhae pollen, 3-5 parts of roasted ginger, 2-4 parts of crinis carbonisatus, 15-20 parts of salviae miltiorrhizae, 15-20 parts of radix codonopsis, 5-8 parts of fructus schizandrae, 8-10 parts of semen cassiae, 10-15 parts of panax notoginseng, 10-15 parts of ganoderma lucidum, 5-8 parts of endothelium corneum gigeriae galli, 15-20 parts of rhizoma atractylodis macrocephalae, 15-20 parts of rhizoma dioscoreae, 8-10 parts of radix gentianae, 15-20 parts of poria cocos, 6-10 parts of semen persicae and 14-18 parts of polygonum multiflorum. The pharmaceutical composition has the advantages that the traditional Chinese medicine materials of the pharmaceutical composition are reasonable in compatibility, yin-yang balance in a body and body resistance strengthening and consolidating are achieved by improving the functions of the internal organs and promoting qi and blood circulation, phlegm evil accumulation is difficult, and effects of removing stasis and phlegm and eliminating numbness and stagnation are achieved.

Description

A kind of pharmaceutical composition treating coronary heart disease and preparation method and application
Technical field
The present invention relates to tcm field, a kind of pharmaceutical composition treating coronary heart disease and preparation method and application.
Background technology
Coronary heart disease is a kind of modal heart disease, refers to the heart caused because of coronary stricture, blood supply insufficiency Flesh malfunction and (or) organic disease, therefore also known as ischemic cardiomyopathy (IHD), its coronary stricture polyphyly fatty material edge Blood vessel is piled up caused, and this process is referred to as arteriosclerosis.Arteriosclerosis develops into a certain degree, and coronary stricture gradually adds Weight, limits the blood flow flowing into cardiac muscle.Heart can not get enough oxygen supplies, chest will be occurred uncomfortable, i.e. angina pectoris.
The Etiological of coronary heart disease is coronary atherosclerosis, but atherosclerotic reason is not fully understood, it may be that many The result of kind of combined factors effect. think that this pathogenetic risk factor has: age and sex (male of more than 45 years old, 55 years old with Upper or postclimacteric women), family history (before 55 years old, mother/sister died from heart disease before 65 years old to father and elder brothers), dyslipidemia (low-density lipoprotein cholesterol LDL-C is too high, and HDL-C HDL-C is too low), hypertension, glucose in urine is sick, smoking, Overweight, obesity, gout, not motion etc..In atherosclerotic common intercurrent disease, blood pressure diseases is undoubtedly when pushing away first place.So Hypertension is undoubtedly the booster of coronary heart disease.
Coronary heart disease is the modal disease of clinic occupying disease death reason front three, serious harm in the range of the Ye Shi world today A kind of common, multiple, the disease that mortality rate is high of public health and life.According to Epidemiological study, at western countries' coronary disease Disease causes death toll to account for the 1/3 of total dead population, in China, along with acceleration and the modern life of social population's aging Socio-psychological factors caused by mode variation increases, and the M & M of coronary heart disease is the most in rising trend, therefore, and coronary disease Sick study on prevention is always difficult point and the emphasis that medical domain is paid close attention to.
The Symptoms of coronary heart disease: owing to pathological changes coronarius is progressively in progress, symptom is also progressively to increase the weight of, and claims clinically For chronic stable angina pectoris；On the other hand, endovascular atheromatous plaque easily forms thrombosis, and microthrombus is permissible Increase the weight of the narrow of tube chamber.If plaque rupture, cause the bigger thrombosis of Ink vessel transfusing, then can make the supported cardiac muscle of this blood vessel Blood flow interrupt suddenly, patient may occur violent chest pain, or even myocardial infarction in a short time, and this situation is referred to as urgency Property coronary syndrome.Therefore, the purpose of coronary heart disease treatment, it is improve symptom and improve long-term prognosis, say, that: one is Angina pectoris symptom for occurring releases as soon as possible, and two is protection coronary artery, prevents Intravascular Thrombus from being formed, the heart after reducing The appearance of myocardial ischemia.The Therapeutic Method of coronary heart disease includes Drug therapy, reperfusion as treatment (thrombolytic, bypass surgery and heart Stent procedure) and heart transplant operation.Existing Drug therapy, generally by rapid coronary artery dilating, increases myocardial blood supply, Improving the present situation of myocardial ischemia, prevent cardiac muscle from necrosing because of ischemia, this mode can only relief of symptoms and stablize the state of an illness or prolong Delaying or alleviate the development process of coronary atherosclerosis, often expand once, blood vessel wall will be more thinning, and the accumulation one of fat Directly increasing, when Fat Accumulation amount reaches the most then can again show effect, and blood vessel wall will not be expanded down always, and this just makes Having become vicious cycle, therefore, existing Drug therapy can not fundamentally treat coronary heart disease, therefore, in the urgent need to research one Plant the medicine of the treatment coronary heart disease that can thoroughly remove old complaint.
Summary of the invention
For solving the defect that prior art exists, can remove what coronary artery and Ink vessel transfusing were piled up it is desirable to provide a kind of Fat, reduces lipids contents and blood viscosity, thoroughly cures Traditional Chinese medicine composition of coronary heart disease and preparation method and application.
To achieve these goals, the technical scheme is that
A kind of Chinese medicine composition treating coronary heart disease, its effective ingredient includes the raw material of following weight portion: Radix Astragali 20-30 part, Pu Yellow 2-3 part, Rhizoma Zingiberis Preparatum 3-5 part, Crinis Carbonisatus 2-4 part, Radix Salviae Miltiorrhizae 15-20 part, Radix Codonopsis 15-20 part, Fructus Schisandrae Chinensis 5-8 part, Semen Cassiae Sub-8-10 part, Radix Notoginseng 10-15 part, Ganoderma 10-15 part, Endothelium Corneum Gigeriae Galli 5-8 part, Rhizoma Atractylodis Macrocephalae 15-20 part, Rhizoma Dioscoreae 15-20 part, dragon Gallbladder 8-10 part, Poria 15-20 part, Semen Persicae 6-10 part, Radix Polygoni Multiflori 14-18 part.
The present invention also has a following additional technical feature:
Preferably, its effective ingredient includes the raw material of following weight portion: the Radix Astragali 25 parts, Pollen Typhae 2 parts, Rhizoma Zingiberis Preparatum 4 parts, Crinis Carbonisatus 3 parts, Radix Salviae Miltiorrhizae 18 parts, Radix Codonopsis 18 parts, Fructus Schisandrae Chinensis 7 parts, Semen Cassiae 9 parts, Radix Notoginseng 12 parts, Ganoderma 12 parts, Endothelium Corneum Gigeriae Galli 7 Part, the Rhizoma Atractylodis Macrocephalae 15 parts, Rhizoma Dioscoreae 18 parts, Radix Gentianae 9 parts, 17 parts of Poria, 8 parts of Semen Persicae, Radix Polygoni Multiflori 16 parts.
Preferably, its effective ingredient includes the raw material of following weight portion: the Radix Astragali 30 parts, Pollen Typhae 2 parts, Rhizoma Zingiberis Preparatum 5 parts, Crinis Carbonisatus 2 parts, Radix Salviae Miltiorrhizae 20 parts, Radix Codonopsis 20 parts, Fructus Schisandrae Chinensis 5 parts, Semen Cassiae 8 parts, Radix Notoginseng 15 parts, Ganoderma 10 parts, Endothelium Corneum Gigeriae Galli 8 Part, the Rhizoma Atractylodis Macrocephalae 15 parts, Rhizoma Dioscoreae 15 parts, Radix Gentianae 8 parts, 15 parts of Poria, 10 parts of Semen Persicae, Radix Polygoni Multiflori 14 parts.
Preferably, its effective ingredient includes the raw material of following weight portion: the Radix Astragali 20 parts, Pollen Typhae 3 parts, Rhizoma Zingiberis Preparatum 3 parts, Crinis Carbonisatus 4 parts, Radix Salviae Miltiorrhizae 15 parts, Radix Codonopsis 15 parts, Fructus Schisandrae Chinensis 8 parts, Semen Cassiae 10 parts, Radix Notoginseng 10 parts, Ganoderma 15 parts, Endothelium Corneum Gigeriae Galli 5 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Rhizoma Dioscoreae 20 parts, Radix Gentianae 10 parts, 20 parts of Poria, 6 parts of Semen Persicae, Radix Polygoni Multiflori 18 parts.
The present invention also provides for the preparation method of a kind of Chinese medicine composition treating coronary heart disease, comprises the following steps: weigh by recipe quantity The Radix Astragali, Pollen Typhae, Rhizoma Zingiberis Preparatum, Crinis Carbonisatus, Radix Salviae Miltiorrhizae, Radix Codonopsis, Fructus Schisandrae Chinensis, Semen Cassiae, Radix Notoginseng, Ganoderma, Endothelium Corneum Gigeriae Galli, the Rhizoma Atractylodis Macrocephalae, Adding the water of material gross mass 4-8 times quality after Rhizoma Dioscoreae, Radix Gentianae, Poria, Semen Persicae, Radix Polygoni Multiflori mixing, first intense fire decocts boiling After, to use slow fire boiling instead 30-40 minute, be filtrated to get for the first time medicinal liquid, medicinal residues boiling again boiling obtains for 10 minutes Secondary medicinal liquid, merges medicinal liquid, filtration, and filtrate is condensed into cream, adds pharmaceutically acceptable adjuvant, according to pharmaceutically conventional system Standby technique makes form of Chinese drug, to obtain final product.
Explanation of nouns: slow fire: refer to little fire, or low baking temperature, for 150-170 DEG C；Intense fire: refer to that firepower is anxious greatly, for 300-500 DEG C.
Preferably, described form of Chinese drug is tablet, pill, capsule, granule, powder or solution.
Further, described pharmaceutically acceptable adjuvant includes starch, Pulvis Talci, magnesium stearate, glucose, Mel, paste Essence, polyvinyl alcohol, Carboxymethyl cellulose sodium, sodium benzoate.
Further, the form of Chinese drug of the present invention is syrup, and when containing 50 DEG C in every 100g syrup, relative density is 1.15 Ointment 30g.
The present invention also provides for the application in the medicine of preparation treatment coronary heart disease of the Chinese medicine composition of above-mentioned treatment coronary heart disease.
The present invention also provides for the application in the medicine of preparation treatment hypertension of the Chinese medicine composition of above-mentioned treatment coronary heart disease, this The mechanism of bright medicine, for removing endovascular lipid accumulation, reduces blood viscosity, is equally applicable to treat hypertension.
The invention have the benefit that the drug matching of the present invention is reasonable, by improving each function, improve QI-blood circulation, Make internal equilibrium between yin and yang, the most just holding up this, making turbid being difficult to of expectorant gather, reach blood stasis dispelling expectorant, eliminate the effect of numbness resistance；The present invention's Medicine can be rapid-action from the most thoroughly treating coronary heart disease, effective, is difficult to recurrence after treatment；Older, fat is coronary heart disease High-risk group, the medicine of the present invention also can do prevention and be used for high-risk group.
The additional aspect of the present invention and advantage will part be given in the following description, and part will become apparent from the description below, Or recognized by the practice of the present invention.
Detailed description of the invention
The invention discloses a kind of pharmaceutical composition treating coronary heart disease and preparation method thereof, those skilled in the art can use for reference this Literary composition content, is suitably modified technological parameter and realizes.Special needs to be pointed out is, all similar replacements and change are to art technology Being apparent from for personnel, they are considered as being included in the present invention.The method of the present invention and application have been passed through the most real Execute example to be described, related personnel substantially can in without departing from present invention, spirit and scope to method described herein and Application.
Embodiment 1
A kind of pharmaceutical composition treating coronary heart disease, weighs the Radix Astragali 25 parts, Pollen Typhae 2 parts, Rhizoma Zingiberis Preparatum 4 parts, Crinis Carbonisatus 3 parts, pellet Join 18 parts, Radix Codonopsis 18 parts, Fructus Schisandrae Chinensis 7 parts, Semen Cassiae 9 parts, Radix Notoginseng 12 parts, Ganoderma 12 parts, Endothelium Corneum Gigeriae Galli 7 parts, white Art 15 parts, Rhizoma Dioscoreae 18 parts, Radix Gentianae 9 parts, 17 parts of Poria, 8 parts of Semen Persicae, Radix Polygoni Multiflori 16 parts；
Adding the water of its 8 times of quality of gross mass after being mixed by above material, intense fire decocts slow fire boiling 40 minutes after seething with excitement, and filters To medicinal liquid for the first time, medicinal residues boiling again boiling obtains second time medicinal liquid for 10 minutes, merges medicinal liquid, filtration, and filtrate concentrates When becoming 50 DEG C, relative density is the ointment of 1.15, and soluble solid content is 35%, add benzoic acid, sorbic acid, Mel and Making syrup after water, the quality of its Chinese medicinal ointment is the 30% of syrup quality.
Instructions of taking is: according to twice daily, each 10g/70kg, anemia of pregnant woman prohibits clothes.
Embodiment 2
A kind of pharmaceutical composition treating coronary heart disease, weighs the Radix Astragali 30 parts, Pollen Typhae 2 parts, Rhizoma Zingiberis Preparatum 5 parts, Crinis Carbonisatus 2 parts, pellet Join 20 parts, Radix Codonopsis 20 parts, Fructus Schisandrae Chinensis 5 parts, Semen Cassiae 8 parts, Radix Notoginseng 15 parts, Ganoderma 10 parts, Endothelium Corneum Gigeriae Galli 8 parts, white Art 15 parts, Rhizoma Dioscoreae 15 parts, Radix Gentianae 8 parts, 15 parts of Poria, 10 parts of Semen Persicae, Radix Polygoni Multiflori 14 parts；
It is prepared as syrup according to the method for embodiment 1.
Embodiment 3
A kind of pharmaceutical composition treating coronary heart disease, weighs the Radix Astragali 20 parts, Pollen Typhae 3 parts, Rhizoma Zingiberis Preparatum 3 parts, Crinis Carbonisatus 4 parts, pellet Join 15 parts, Radix Codonopsis 15 parts, Fructus Schisandrae Chinensis 8 parts, Semen Cassiae 10 parts, Radix Notoginseng 10 parts, Ganoderma 15 parts, Endothelium Corneum Gigeriae Galli 5 parts, white Art 20 parts, Rhizoma Dioscoreae 20 parts, Radix Gentianae 10 parts, 20 parts of Poria, 6 parts of Semen Persicae, Radix Polygoni Multiflori 18 parts；
It is prepared as syrup according to the method for embodiment 1.
Embodiment 4
The ointment obtained in embodiment 1 addition conventional pharmaceutical adjuvants is prepared as tablet according to common process.
Embodiment 5
The ointment obtained in embodiment 1 addition conventional pharmaceutical adjuvants is prepared as pill according to common process.
Embodiment 6
The ointment obtained in embodiment 1 addition conventional pharmaceutical adjuvants is prepared as granule according to common process.
Embodiment 7 toxicity test
The syrup of embodiment 1 preparation is carried out toxicity test, and animal subject is rabbit, and body weight is 1.8-2.2kg, by Shandong Province Laboratory provide, totally 40, male and female half and half, be divided into four groups, will syrup dilute after with syringe draw carry out gavage 20 days, observe the activity of animal during gavage, defecation, feed, fur have without exception, after gavage terminates, put to death rabbit, solve Cut open observation liver, kidney, heart have without exception.
High dose group: every day gavage once, take 23g syrup every time, be equivalent to 40 times of people's dosage every day；
Middle dosage group: every day gavage once, take 11.5g syrup every time, be equivalent to 20 times of people's dosage every day；
Low dose group: every day gavage once, take 5.7g syrup every time, be equivalent to 10 times of people's dosage every day；
Matched group: the adjuvant materials of syrup, without ingredient.
Experimental result: during gavage, tested group of rabbit and the activity of negative control group, defecation, feed, fur are the most without exception； After dissection, the liver of four treated animals, kidney, heart are the most without exception.
The medicine of embodiment 8 present invention therapeutic effect to Atherosclerosis in Rabbits
Owing to the absorbance of rabbit exogenous cholesterol is high, up to 75-95%, and rat only has 40%, therefore the present invention Test selects rabbit to be animal pattern, and body weight is 1.8-2.2kg, sets up the method for model with reference to paper rabbit arterial medicated porridge samples such as Wang Yuanyuan The foundation of hardened tallow model and evaluation.
Testing index: serum total cholesterol (TC), serum triglycerides (TG), high density lipoprotein (HDL-C) and pathology detection.
Experiment packet: normal group, experimental group, negative control group, often group ten, wherein experimental group is gavage present invention every day The syrup of embodiment 1, every day 2 times, each 1g, normal group and negative control group all take the adjuvant of syrup, without drug effect Composition.
Test period is 8 weeks, puts to death rabbit, Detection results such as table 1 after 8 weeks.
The therapeutic effect of table 1 Atherosclerosis in Rabbits
Packet TC(mmol/L) TG(mmol/L) HDL-C(mmol/L)
Normal group 4.40±0.33 0.70±0.087 3.25±0.074
Experimental group 4.47±0.46 0.71±0.126 3.24±0.023
Negative control group 23.52±0.98 7.2±0.112 2.77±0.104
Case monitoring result: experimental group compared with negative control group, the densification smooth, smooth of experimental group blood vessel, negative control group blood Pipe Aldosterone, tube wall occurs that adipose cell is piled up and speckle, and existing calcification phenomenon.
From table 1, experimental group and negative control group difference are extremely notable, not notable with normal group difference, therefore, and the present invention's Drugs on atherosclerotic has preferable therapeutic effect, it is possible to significantly reduce lipids contents, protects blood vessel wall, vessel softening, And improve lipid accumulation.
The medicine of embodiment 9 present invention preventive effect to Atherosclerosis in Rabbits
Experimental technique: selecting rabbit as animal pattern, body weight is 1.8-2.2kg；
Testing index is with embodiment 8；
Experiment packet: experimental group and matched group, often group ten, experimental group and matched group all set up the side of model according to embodiment 8 Method processes, and wherein, experimental group takes the syrup of embodiment 1, every day 2 times every day, and each 1g, matched group takes syrup Adjuvant, without active ingredient；
Experimental result: experimental group and matched group index parameter are to such as table 2.
Table 2 experimental group and the contrast of matched group index parameter
Packet TC(mmol/L) TG(mmol/L) HDL-C(mmol/L)
Experimental group 4.44±0.45 0.71±0.110 3.25±0.097
Matched group 24.37±0.98 6.8±0.134 2.75±0.091
From table 2, the physiochemical indice of the experimental group and matched group of taking medicine of the present invention has marked difference, the index of experimental group Normally, and the parameter of matched group is partial to more greatly normal range, therefore, it can draw, coronary heart disease is had relatively by the medicine of the present invention Good preventive effect, and without any side effects, except anemia of pregnant woman.
Embodiment 10 clinical trial
100, the court patients with coronary heart disease being carried out random packet, often organizes 50 examples, A group takes the syrup of the present invention, and B group takes By drugs compared, comparative example is Western medicine, observes one month, according to following standard determination curative effect:
Criterion:
Effective: physical distress disappears, Electrocardiography is normal, T ripple by being inverted, low flat turn is upright；
Effective: pain relief or attack times pain number of times reduce, and electrocardiogram moves down, rise 0.05mv after the treatment of ST section, but Not up to normal level；
Invalid: pain symptom is not alleviated, electrocardiogram is without changing.
The present invention is as shown in table 3 with the therapeutic effect of comparative example:
Table 3 Comparison of therapeutic
Packet Number (people) Effective (people) Effectively (people) Invalid (people) Effective percentage (%)
Embodiment 1 50 16 29 5 90
Comparative example 50 6 27 17 66
Table 3 is visible, and the medicine of the present invention is effective and effect level is all apparently higher than comparative example, and total effective rate reaches 90%, and nothing Any side effect, patient uses comfort good, after patient's after treatment one week, follows the tracks of and observes 2 years, have no recurrence.
The above is only the preferred embodiment of the present invention, it is noted that for those skilled in the art, Under the premise without departing from the principles of the invention, it is also possible to make some improvements and modifications, these improvements and modifications also should be regarded as this Bright protection domain.

Claims (8)

1. the Chinese medicine composition treating coronary heart disease, it is characterized in that, its effective ingredient includes the raw material of following weight portion: Radix Astragali 20-30 part, Pollen Typhae 2-3 part, Rhizoma Zingiberis Preparatum 3-5 part, Crinis Carbonisatus 2-4 part, Radix Salviae Miltiorrhizae 15-20 part, Radix Codonopsis 15-20 part, Fructus Schisandrae Chinensis 5-8 part, Semen Cassiae 8-10 part, Radix Notoginseng 10-15 part, Ganoderma 10-15 part, Endothelium Corneum Gigeriae Galli 5-8 part, Rhizoma Atractylodis Macrocephalae 15-20 part, Rhizoma Dioscoreae 15-20 part, Radix Gentianae 8-10 part, Poria 15-20 part, Semen Persicae 6-10 part, Radix Polygoni Multiflori 14-18 part.
The Chinese medicine composition for the treatment of coronary heart disease the most according to claim 1, it is characterized in that, its effective ingredient includes the raw material of following weight portion: the Radix Astragali 25 parts, Pollen Typhae 2 parts, Rhizoma Zingiberis Preparatum 4 parts, Crinis Carbonisatus 3 parts, Radix Salviae Miltiorrhizae 18 parts, Radix Codonopsis 18 parts, Fructus Schisandrae Chinensis 7 parts, Semen Cassiae 9 parts, Radix Notoginseng 12 parts, Ganoderma 12 parts, Endothelium Corneum Gigeriae Galli 7 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Rhizoma Dioscoreae 18 parts, Radix Gentianae 9 parts, 17 parts of Poria, 8 parts of Semen Persicae, Radix Polygoni Multiflori 16 parts.
The Chinese medicine composition for the treatment of coronary heart disease the most according to claim 1, it is characterized in that, its effective ingredient includes the raw material of following weight portion: the Radix Astragali 30 parts, Pollen Typhae 2 parts, Rhizoma Zingiberis Preparatum 5 parts, Crinis Carbonisatus 2 parts, Radix Salviae Miltiorrhizae 20 parts, Radix Codonopsis 20 parts, Fructus Schisandrae Chinensis 5 parts, Semen Cassiae 8 parts, Radix Notoginseng 15 parts, Ganoderma 10 parts, Endothelium Corneum Gigeriae Galli 8 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Rhizoma Dioscoreae 15 parts, Radix Gentianae 8 parts, 15 parts of Poria, 10 parts of Semen Persicae, Radix Polygoni Multiflori 14 parts.
The Chinese medicine composition for the treatment of coronary heart disease the most according to claim 1, it is characterized in that, its effective ingredient includes the raw material of following weight portion: the Radix Astragali 20 parts, Pollen Typhae 3 parts, Rhizoma Zingiberis Preparatum 3 parts, Crinis Carbonisatus 4 parts, Radix Salviae Miltiorrhizae 15 parts, Radix Codonopsis 15 parts, Fructus Schisandrae Chinensis 8 parts, Semen Cassiae 10 parts, Radix Notoginseng 10 parts, Ganoderma 15 parts, Endothelium Corneum Gigeriae Galli 5 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Rhizoma Dioscoreae 20 parts, Radix Gentianae 10 parts, 20 parts of Poria, 6 parts of Semen Persicae, Radix Polygoni Multiflori 18 parts.
5. the preparation method of the Chinese medicine composition of the treatment coronary heart disease described in any one of claim 1-4, it is characterized in that, comprise the following steps: weigh the Radix Astragali by recipe quantity, Pollen Typhae, Rhizoma Zingiberis Preparatum, Crinis Carbonisatus, Radix Salviae Miltiorrhizae, Radix Codonopsis, Fructus Schisandrae Chinensis, Semen Cassiae, Radix Notoginseng, Ganoderma, Endothelium Corneum Gigeriae Galli, the Rhizoma Atractylodis Macrocephalae, Rhizoma Dioscoreae, Radix Gentianae, Poria, Semen Persicae, the water of material gross mass 4-8 times quality is added after Radix Polygoni Multiflori mixing, after first intense fire decocts boiling, use slow fire boiling instead 30-40 minute, it is filtrated to get medicinal liquid for the first time, medicinal residues boiling again boiling obtains second time medicinal liquid for 10 minutes, merge medicinal liquid, filter, filtrate is condensed into cream, add pharmaceutically acceptable adjuvant, form of Chinese drug is made according to pharmaceutically conventional fabrication process, obtain.
The preparation method of the Chinese medicine composition for the treatment of coronary heart disease the most according to claim 5, it is characterised in that described form of Chinese drug is tablet, pill, capsule, granule, powder or solution.
7. the Chinese medicine composition of the treatment coronary heart disease described in any one of claim 1-4 application in the medicine of preparation treatment coronary heart disease.
8. profit requires the application in the medicine of preparation treatment hypertension of the Chinese medicine composition of the treatment coronary heart disease described in any one of 1-4.
CN201610383024.9A 2016-06-02 2016-06-02 Pharmaceutical composition for treating coronary heart disease and preparation method and application thereof Pending CN105833237A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610383024.9A CN105833237A (en) 2016-06-02 2016-06-02 Pharmaceutical composition for treating coronary heart disease and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610383024.9A CN105833237A (en) 2016-06-02 2016-06-02 Pharmaceutical composition for treating coronary heart disease and preparation method and application thereof

Publications (1)

Publication Number Publication Date
CN105833237A true CN105833237A (en) 2016-08-10

Family

ID=56596178

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610383024.9A Pending CN105833237A (en) 2016-06-02 2016-06-02 Pharmaceutical composition for treating coronary heart disease and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN105833237A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1546067A (en) * 2003-09-15 2004-11-17 史 忠 Chinese traditional medicine for treating coronary disease and angina
CN104740289A (en) * 2013-12-26 2015-07-01 曹红云 Traditional Chinese medicine for treating coronary heart disease
CN104887900A (en) * 2015-05-13 2015-09-09 河南省新境界酒业有限公司 Health care wine with effects of fat reducing and weight losing

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1546067A (en) * 2003-09-15 2004-11-17 史 忠 Chinese traditional medicine for treating coronary disease and angina
CN104740289A (en) * 2013-12-26 2015-07-01 曹红云 Traditional Chinese medicine for treating coronary heart disease
CN104887900A (en) * 2015-05-13 2015-09-09 河南省新境界酒业有限公司 Health care wine with effects of fat reducing and weight losing

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘兰霞: "补心活血汤治疗老年冠心病心绞痛40例", 《辽宁中医学院学报》 *

Similar Documents

Publication Publication Date Title
CN100366280C (en) Medicinal composition for treating hypertension, its preparation method and use
CN103919854B (en) Application of butterflybush flower and extract thereof to preparation of medicament
CN101129773A (en) Granular formulation, tablet or capsule of black-bone chicken and white phoenix and method of preparing the same
CN101433568A (en) Extraction of burdock root aqueous extract and use
CN102526423A (en) Medicine composition for treating ischemic heart disease
CN101347584A (en) Medicament for treating primary hypertension and preparation method thereof
JP7340113B2 (en) Chinese herbal composition and its production method and use
CN102008688B (en) Medicament for treating periodic psychosis
CN105833237A (en) Pharmaceutical composition for treating coronary heart disease and preparation method and application thereof
CN103768129B (en) Drug composition for preventing or treating hypertension
CN102657827A (en) Traditional Chinese medicine used for treating liver and gall diseases and preparation method thereof
CN106109951A (en) Prevent and treat medicine of hyperglycemia, hyperlipidemia, hypertension and preparation method thereof
CN105664133A (en) Oral solid preparation for treating hypertension and preparing method thereof
CN105456652A (en) Traditional Chinese medicine preparation for treating dyslipidemia and coronary heart disease and preparation method thereof
CN108743885A (en) A kind of Chinese medicine and preparation method thereof for treating Diabetic Macrovascular Complications
CN108815365A (en) A kind of Chinese medicine composition for treating hypertension
CN104306579B (en) A kind of Chinese medicine for treating deficiency of yin and stagnation of blood diabetic retinopathy and preparation method and application
CN108210595A (en) Treat Chinese medicine composition of acute-on-chronic liver failure and its preparation method and application
CN114767794B (en) Traditional Chinese medicine for treating arterial plaque
CN116570702B (en) Traditional Chinese medicine composition for resisting ejection fraction retention type heart failure and application thereof
CN101991799B (en) Medicine for treating nephritis
CN107468849A (en) A kind of medicine for treating chronic renal failure and preparation method thereof
CN102552481A (en) Traditional Chinese medicinal composition with effects of smoothing collaterals and lowering blood pressure and preparation method thereof
CN104784530A (en) Traditional Chinese medicine extract capable of reducing blood pressure and preparation method of extract
CN105853497A (en) Preparation method of medicine for treating hypertension, coronary heart disease and coronary artery atherosclerosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160831

Address after: 276400 No. 17, health Road, Yishui County, Shandong, Linyi

Applicant after: Yishui Central Hospital of Linyi

Address before: 276401 No. 17, health Road, Yishui County, Shandong, Linyi

Applicant before: Yao Zongqin

RJ01 Rejection of invention patent application after publication

Application publication date: 20160810

RJ01 Rejection of invention patent application after publication